Analysis of the risk-factors of cardio-vascular disease in Russia and its regions

© 2014 by the author(s). For the long time in the structure of the mortality reasons the dominant role belongs to the circulatory diseases, which are determine more than half of the deaths. At the same time, the situation differs in different countries and there are evidences that in most of the developed countries the rate of the deaths caused by cardio-vascular diseases is significantly lower than in Russia. It's necessary to organize further researches dedicated to the determination of the risk factors in Russia and its regions to determine the causes of deaths

The use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

© 2014 the author(s). The article presents high clinical efficiency and the absence of side effects of the use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

Cleek Installation

Award giving at the Cleek installatio

The use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

© 2014 the author(s). The article presents high clinical efficiency and the absence of side effects of the use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

Analysis of the risk-factors of cardio-vascular disease in Russia and its regions

© 2014 by the author(s). For the long time in the structure of the mortality reasons the dominant role belongs to the circulatory diseases, which are determine more than half of the deaths. At the same time, the situation differs in different countries and there are evidences that in most of the developed countries the rate of the deaths caused by cardio-vascular diseases is significantly lower than in Russia. It's necessary to organize further researches dedicated to the determination of the risk factors in Russia and its regions to determine the causes of deaths

The use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

© 2014 the author(s). The article presents high clinical efficiency and the absence of side effects of the use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

The use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

© 2014 the author(s). The article presents high clinical efficiency and the absence of side effects of the use of histochrome in the complex treatment of the patients with acute coronary syndrome with ST segment depression diagnosed on ECG

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension

Aim. To assess atorvastatin lipid-lowering effect and tolerability at the initial stage of lipid-lowering treatment. Material and methods. The study included 47 patients (14 women, 33 men; mean age 55,6±11,6 years). Inclusion criteria were: verified coronary heart disease, CHD (stable effort angina, post-infarction cardiosclerosis), total cholesterol (TCH) level >5,0 mmol/l, low-density lipoprotein (LDL) CH level >3,0 mmol/l, triglycerides (TG) level _<3,5 mmol/l. CHD was verified in 31 patients (62%), including 17 with previous myocardial infarction (MI); 38 participants (76%) had arterial hypertension, 30 (60%) were overweight. All patients received atorvastatin (10 mg/d), individuals with CHD also received clopidogrel (75 mg/d). The follow-up period lasted for one month. After 14 days and one month of the therapy, lipid profile and liver function tests (LFT) were performed. Results. Thirty-day lipid-lowering therapy resulted in decreased TCH level (by 33,2%; p<0,01), reduced LDL-CH concentration (by 33,9%; p<0,05), elevated high-density lipoprotein (HDL) CH level (by 18,5%; p<0,05), and decreased atherogenicity index (by 38,4%; p<0,05). During one-month follow-up, no significant changes in LFT were observed. Conclusion. As early as during the first month of the treatment, lipid-lowering therapy with atorvastatin resulted in significant reduction in TCH, LDL-CH, and TG concentrations, together with increase in HDL-CH level. No effect on FLT was observed